A state of collaboration
The combined strengths of the institutions that make up the UM System uniquely position Missouri to be a global leader in developing the urgently needed cures and treatments of the future. Our strength lies in our network of highly skilled researchers, existing partnerships and modern facilities — strengths that allow us to streamline the perilous journey from laboratory research to accessible and effective medical solutions.
The University of Missouri–Columbia (MU), the only public Association of American Universities member and Research 1 university in the state, operates the most powerful university research reactor in the country. MU Research Reactor (MURR®) is the nation’s sole producer of active ingredients in several FDA-approved radiopharmaceuticals. MU researchers direct breakthrough studies of animal models and data science on a scale simply not available to most universities, because of the NIH-supported Rat, Swine and Mutant Mouse Resource and Research Centers. On the clinical side, the MU Health Care system is an international destination for groundbreaking patient therapies. Moreover, MU is one of only six public universities in the country with divisions dedicated to medicine, veterinary medicine, agriculture, engineering and law, plus a research reactor all on one campus. MU’s unique convergence of resources demonstrates its power to make a major global impact.
The University of Missouri-Kansas City (UMKC) merges diverse research areas to rapidly move discoveries from the laboratory to the patient’s bedside to the marketplace. The university‘s deep strengths in data science and bioinformatics have transformed patient care in the Kansas City area. Additionally, the UMKC School of Dentistry has attracted international attention for pioneering studies and unique research collaborations at the crossroads of dentistry, engineering and medicine.
Missouri University of Science and Technology (Missouri S&T) excels in interdisciplinary collaboration and pioneered new precision cancer treatments decades before the term “precision medicine” was widely used. In 1988, collaborating researchers from Missouri S&T and MU received a patent for the technology to create a new drug for inoperable liver cancer, and led to the MO-SCI Corporation based in Rolla. MO-SCI continues to develop innovative medical treatments, such as a glass-based wound-healing matrix that began as research in Missouri S&T labs.
The University of Missouri–St. Louis (UMSL) offers mental health and addiction sciences programs that have helped slow the rising tide of opioid overdose deaths across the state. UMSL researcher Dr. Rachel Winograd works at the Missouri Institute of Mental Health (MIMH) to lead evidence-based approaches across the state that have attracted more than $60 million in external funding in only a few years. Researchers at MIMH also focus on advanced neuroimaging methods, integration of biomarkers and genetics, and identifying causes of disease to build predictive models for individualized therapeutics.